No consensus was reached regarding the prescription of SGLT2 inhibitors to all patients with diabetes (regardless of ulceration status), or similarly to patients with type 2 diabetes with glycaemic control above target with/without atherosclerotic cardiovascular disease. This evidence concerns the gene SLC5A2 and diabetes mellitus.